Back to the overview page

Annemarie (A) van de Geer

Department
Blood Cell Research
E-mail
a.vandegeer@sanquin.nl
LinkedIn
https://www.linkedin.com/pub/annemarie-van-de-geer/a8/b16/637
Training

Medicine; Law

Research interests
(Intensive) chemotherapy can result in a reduced production of white blood cells (immune cells), especially neutrophils. These neutrophils are essential in the defence against bacteria and fungi. Patients with longstanding neutropenia run the risk of developing a life-threatening infection. Administration of neutrophils from healthy donors is an effective way to fight such infections in case antibiotic and/or antifungal therapy fails. However, patients themselves need to recruit these donors, which are subjected to extensive medical screening and dexamethasone/growth hormone (GCSF) therapy. This is a time consuming, cumbering procedure for the patient, family, doctor and donor, with unknown long term effects of the GCSF. Therefore, we are trying to develop a new granulocyte transfusion product, from residual pooled buffy coats, which we will compare to the standard G-CSF/dexamethasone product. Also, we will perform a biomarkerstudy in adult hematology patients in order to refine the timing, indications and eligible patients for granulocyte transfusions.
Technology
  • Blood cell isolation
  • Granulocyte function assays
  • Western blotting
  • In vitro microbiocidal killing
  • Flow cytometry
  • ELISA
Resume
2014-present PhD student at Dept Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands
2013-2014 Registrar pediatrics, Flevoziekenhuis Almere
2011 Research project Dept of Endocrinology, Children’s Hospital Boston, Harvard University, Boston MA, USA
2007-2013 Medicine, University of Amsterdam, Cum Laude
2007-2013 Bachelor of Laws, University of Amsterdam
Publications
Sanquin publications
Other publications

Kleinjan A, Aggarwal A, van de Geer A, Faselis C, Büller HR, Di Nisio M, Rickles FR, Kamphuisen PW. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thromb Haemost 2013; 110(5):959-65.

Last edited on: 21 April 2016
Back to the overview page